US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT05627466 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

DRUG: Magrolimab

Sponsor

Gilead Sciences